This will lead to more accurate genotyping, prediction, early assessment of response, and minimal residual disease.
Welcome to Research
We aim to improve outcome for patients with solid cancer, particular for targeted- and immunotherapies, by use of more accurate and novel molecular diagnostics.
See some of the most important goals for this research program.
Richarda de Voer's research group focuses on the genetic predispositions and mutational processes that underly cancer development, especially in the context of development at an early age in Iife and concerning the development of multiple primary tumors throughout the life of a single individual.
Nielka van Erp's research group focuses on describing, explaining, understanding and modifying the pharmacokinetics of oral anticancer drugs.
Jack Schalken's research group focuses on preclinical models for cancer, precision medicine by molecular diagnostics, with a focus on prognostic- and predcitive biomarkers and on GU oncology and salivary gland cancer.
dr. Niven Mehra